Prestige Brands Holdings was founded in 1996 and is headquartered in Irvington, New York. Prestige Brands Holdings, Inc. (Prestige) sells over-the-counter healthcare, household cleaning and personal care products in a global marketplace. The Company’s products are sold through multiple channels, including mass merchandisers and drug, grocery, dollar and club stores, which allow it to launch products across all distribution channels and reduce its exposure to any single distribution channel. The Company conducts its operations through three principal business segments: over-the-counter healthcare, household cleaning and personal care. During the fiscal year ended March 31, 2009 (fiscal 2009), Prestige’s principal brands accounted for approximately 94.5% of its net revenues.

Morphotek has mighty morphin' power, but don't expect to find its products on the shelves of the local toy store. The biotechnology company develops monoclonal antibody (single-source protein) therapies for the treatment of cancer, inflammation, and infectious diseases using its proprietary Morphogenics technology platform. It conducts research and clinical development programs on its own drug candidates for ailments such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. Morphotek also enters collaborative research partnerships and licenses out its technology to other drug companies such as Amgen and Novo Nordisk. The company is a subsidiary of Eisai Inc., part of Japanese drug firm Eisai.

Tercica, Inc. company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A. Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA.

AstraZeneca was founded in 1992 and is headquartered in London, the United Kingdom. AstraZeneca plc (LSE: AZN) operates independently of Imperial Chemical Industries plc as of June 1, 1993. AstraZeneca plc discovers, develops, manufactures, and markets prescription pharmaceuticals and biological products in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide. Its primary products include Arimidex for hormonal breast cancer; Crestor that provides treatment for managing cholesterol levels; Nexium for acid-related diseases; Seroquel, an atypical anti-psychotic therapy for treating schizophrenia and bipolar mania; and Symbicort for the treatment of asthma in patients.AstraZeneca company also engages in the research, development, manufacture, and marketing of medical devices and implants for use in urology, surgery, and odontology. In addition, it develops and manages hospital-based outpatient cancer centers in the United States; and produces individually adapted abutments for dental implants using a patented CAD/CAM method. The company markets its products to primary care and specialist physicians, as well as to other healthcare professionals, governments, and healthcare buying groups through sales and marketing network, local marketing companies, distributors, and local representative offices. It has collaboration agreements with Bristol-Myers Squibb Company; POZEN Inc.; Abbott laboratories; Palatin Technologies, Inc; BioDuro Inc.; Jubilant Organosys Ltd.; Merck & Co. Inc.; Cancer Research Technology Limited; Institute of Cancer Research; Alcon Inc.; Mental Health Research Institute; Targacept, Inc.; and Dako Denmark A/S. AstraZeneca also has a drug discovery and development agreement with PsychoGenics Inc. to identify compounds that are useful for the treatment of certain central nervous system disorders.

Cytokinetics, Incorporated company was founded in 1997 and is headquartered in South San Francisco, California. Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule drug therapeutics for the treatment of cardiovascular diseases and cancer. The company’s lead product includes CK-1827452, a cardiac muscle myosin activator, which is in Phase IIa clinical trials for the treatment of heart failure. Its products under development stage comprise Ispinesib, a kinesin spindle protein inhibitor that is in Phase I/II clinical trials for the treatment of metastatic breast cancer; SB-743921, which is in Phase I/II trials to treat patients with non-Hodgkin or Hodgkin lymphoma; and GSK-923295, centromere-associated protein E inhibitor, which is in Phase I clinical trials to treat patients with refractory solid tumors. The company’s products under preclinical stage consist of CK-2017357, a skeletal sarcomere activator for the treatment of diseases and conditions associated with muscle weakness or wasting; and smooth muscle myosin inhibitor for the treatment of pulmonary arterial hypertension, and diseases and medical conditions associated with bronchoconstriction. It has a strategic alliance with Amgen Inc. to discover, develop, and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure, as well as with GlaxoSmithKline to develop GSK-923295.

A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company’s primary focus is on its lead product candidate, APF530, which completed a pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the year ended December 31, 2008. APF530 is designed to prevent CINV for at least five days and contains granisetron, a drug approved for the prevention of CINV. In addition to its lead drug candidate, A.P. Pharma has a pipeline of other product candidates that use its Biochronomer technology. One of these, APF112, incorporates the local anesthetic, mepivacaine. It is designed to provide up to 36 hours of post-surgical pain relief and to minimize the use of morphine-like drugs, or opiates, which are used in post-surgical pain management.

Brothers Charles and Theophil Gebauer founded the company in 1898. Gebauer's Salivart will make your mouth water. Seriously, that's what it's designed to do for people who suffer from xerostomia, better known as dry mouth. That's not all Gebauer makes, however. The company offers medications for topical use, including Ethyl Chloride for the treatment of pain; Instant Ice, for the relief of muscle spasms, strains, bruising, and other injuries; and Spray and Stretch, for myofacial pain and minor sports injuries. Gebauer also provides contract manufacturing as well as project planning, packaging and labeling, and distribution services for other drug makers.

Medivation, Inc. was founded in 2003 and is based in San Francisco, California. Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and castration-resistant prostate cancer. Its product pipeline includes Dimebon, which is in pivotal Phase 3 trial in patients with mild-to-moderate Alzheimer's disease, and is in Phase 2 clinical trial in patients with mild-to-moderate Huntington's disease; and MDV3100, a Phase 1-2 clinical trial product in patients with castration-resistant prostate cancer. The company has a collaboration agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases, as well as an agreement to develop and commercialize MDV3100, an investigational drug for the treatment of prostate cancer.

MaxCyte will put your blood cells to work. Its cell loading technology uses blood cells instead of viral vectors to transport gene therapies to target sites, increasing their safety and efficacy. The company partners with drug makers to help them develop more effective therapies in a shorter amount of time. Partners include AlphaVax, Sangamo BioSciences, and United Therapeutics. MaxCyte is also working on its own therapies, including potential treatments for chronic lymphocytic leukemia, lymphoma, and breast and ovarian cancer. CEO Douglas Doerfler and other backers control the company after EntreMed spun it off.

QUATRx Pharmaceuticals hopes to capitalize on the bright ideas of others. The biopharmaceutical company acquires compounds in the pre-clinical stage from other companies and academic institutions and takes them through clinical studies then licensing them to pharma giants. The company focuses on developing new therapies for cardiovascular, endocrine, and metabolic conditions. Products in clinical trials include treatments for age-related hormone deficiencies in women and men as well as drugs for high cholesterol and the treatment of psoriasis. Hormos Medical, QUATRx's Finnish subsidiary, conducts most of its preclinical and discovery programs.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.